Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke

Pfizer IncPfizer Inc announced that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg. This finding is from a subanalysis designed and completed following the closure of the five-year Treating to New Targets (TNT) study in patients with existing coronary heart disease. The results were published in the August issue of Mayo Clinic Proceedings.

"As the rates of diabetes in the U.S. have risen, we have seen a dramatic increase in the number of cases of chronic kidney disease," said Dr. James Shepherd, clinical academic consultant, department of pathological biochemistry, University of Glasgow Medical School and a member of the TNT steering committee. "This trend is alarming, since patients with diabetes and chronic kidney disease are much more likely to suffer a heart attack or stroke than patients with diabetes alone, increasing the urgency to treat. The study's findings support existing guidelines that recommend aggressively lowering LDL cholesterol using statin therapy, such as Lipitor 80 mg, to reduce the likelihood of a heart attack or stroke in these high-risk patients."

In patients with heart disease and type 2 diabetes but without chronic kidney disease, Lipitor 80 mg reduced the risk of major cardiovascular events by 10 percent compared to Lipitor 10 mg, which did not reach significance.

Both doses of Lipitor (80 mg and 10 mg) were generally well tolerated.

About the TNT Study
The TNT study was an investigator-led trial coordinated by an independent steering committee and funded by Pfizer. The study enrolled 10,001 men and women with coronary heart disease aged 35 years to 75 years in 14 countries and followed them for an average of five years.

The primary endpoint of the TNT study was the occurrence of a first major cardiovascular event, defined as death from heart disease, non-fatal heart attacks, resuscitated cardiac arrest, or fatal or non-fatal strokes.

This post-hoc subanalysis studied the effect of Lipitor 80 mg on the incidence of major cardiovascular events compared with Lipitor 10 mg in patients with heart disease and type 2 diabetes, with chronic kidney disease (n=546) and without chronic kidney disease (n=885). Patients with chronic kidney disease were defined as having a baseline glomerular filtration rate below 60 mL/min/1.73 m2 using a standard measure of kidney function. Lipitor 80 mg is not a starting dose.

About Type 2 Diabetes
Type 2 diabetes is the most common form of diabetes, according to the American Diabetes Association, and is reaching epidemic proportions across the world. Europe alone counts more than 25 million people with type 2 diabetes. In the U.S., nearly 24 million people have type 2 diabetes, equating to almost eight percent of the population.

According to the Centers for Disease Control, heart disease and stroke account for about 65 percent of deaths in people with type 2 diabetes in the U.S. Adults with type 2 diabetes have heart disease death rates that are approximately two to four times higher than that of adults without diabetes.

About Type 2 Diabetes and Chronic Kidney Disease
Diabetes is the leading cause of chronic kidney disease in the U.S. and accounts for about 38 percent of Americans being treated for kidney failure. Patients with chronic kidney disease do not effectively filter toxins from the blood. When chronic kidney disease progresses to kidney failure, either dialysis or a kidney transplant is needed.

According to the National Kidney Foundation guidelines, the outlook for those with both diabetes and chronic kidney disease is far worse than for patients with either condition alone, as the combination is a powerful predictor of major cardiovascular events such as heart attack and stroke.

About Lipitor
Only Lipitor offers these three benefits important in a statin: FDA approval to reduce the risk of heart attacks, strokes and certain types of heart surgery in patients with cardiovascular risk or with heart disease; the ability to reduce "bad" cholesterol (LDL) by 39 percent to 60 percent; and a well-established safety profile across a broad range of patients.

It is the most prescribed branded cholesterol-lowering therapy in the world, with more than 151 million patient-years of experience. Lipitor is supported by a 16-year clinical trial program involving more than 400 ongoing and completed trials with more than 80,000 patients.

For additional product information, visit www.Lipitor.com.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...